Search

Displaying results 4161 - 4170 of 7455 in total
  1. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).

  2. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    However, there currently are no clinical indications for preferential use of ridogrel over aspirin. … Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  3. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    It is developed for the treatment of osteoporosis.

  4. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  5. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  6. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Elevated LDL-C is a principal modifiable risk factor for atherosclerotic cardiovascular disease, and cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk of … major adverse cardiovascular events in at-risk adults treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy.

  7. Drug

    Bromochlorosalicylanilide

    go.drugbank.com/drugs/DB13696
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    Navarixin

    go.drugbank.com/drugs/DB11711
    Investigational

    Navarixin has been investigated for the treatment of Asthma.

  9. Drug

    Sarcosine

    go.drugbank.com/drugs/DB12519
    Investigational

    Sarcosine has been investigated for the treatment of Schizophrenia.

  10. Drug

    Pyronaridine

    go.drugbank.com/drugs/DB12975
    Investigational

    Pyronaridine has been investigated for the treatment of Malaria.